ANTARES PHARMA, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Net loss
Cash Flows from Operating Activities
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Deferred taxes
Stock-based compensation
Depreciation and amortization
Accretion of interest expense
Amortization of debt issuance costs
Amortization of premiums and discounts on investment securities
Non-cash interest expense
Increase in inventory reserve
Gain on sale of assets
Loss on disposal of equipment
Write-off of capitalized patent costs
Other
Changes in operating assets and liabilities:
Accounts receivable
Inventories, net
Contract assets
Prepaid expenses and other current assets
Deferred costs
Other assets
Accounts payable
Accrued expenses and other liabilities
Deferred revenue

Net cash used in operating activities
Deferred revenue
Net cash provided by (used in) operating activities

Cash Flows from Investing Activities
Purchases of property and equipment
Proceeds from sale of assets, net of transaction costs
Purchase of intangibles, including transaction costs
Purchases of investment securities
Proceeds from maturities of investment securities
Net cash provided by (used in) investing activities
Cash Flows from Financing Activities
Proceeds from issuance of long-term debt
Principal payments of long-term debt
Prepayment fees and end of term charge on long-term debt
Payment of debt issuance costs for long-term debt
Proceeds from issuance of common stock, net
Proceeds from exercise of stock options
Taxes paid related to net share settlement of equity awards
Net cash provided by financing activities
Effect of exchange rate changes on cash
Net decrease in cash and cash equivalents
Net cash provided by (used in) financing activities

Effect of exchange rate changes on cash and cash equivalents
Cash and cash equivalents
Net increase (decrease) during the period
Beginning of period
End of period
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of non-cash investing activities
Purchases of property and equipment recorded in accounts payable and accrued expenses
Additions to patent rights recorded in accounts payable and accrued expenses
Purchase of intangible assets included in accrued liabilities
Gain on sale of assets recognized in excess of cash received

Comments